AzTrials
AzTrials

Heart FailureLINK-HF2NCT04502563

LINK-HF2 - Remote Monitoring Analytics in Heart Failure

A study testing Remote monitoring and predictive analytics in people with Heart Failure, run by VA Office of Research and Development at 4 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Heart failure (HF) is a type of heart disease that leads to need of admissions to the hospital during worsening of symptoms. These admissions are expensive and very inconvenient for patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure
What is being tested?
Remote monitoring and predictive analytics
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
176 participants
Where
4 sitesUnited States
Study dates
19 Apr 2021to 30 Oct 2024
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject must be 18 years old or older
  • New York Heart Association Functional Classification Class II-IV, documented in site's medical record system.
  • Subject able and willing to sign Informed Consent Document, and if participating in a patient interview, able to comprehend and agree with items listed in the VA Consent Cover Letter.
  • Subject willing and able to perform all study related procedures.

Who cannot join

  • Expected Left Ventricular Assist Device implantation or heart transplantation in the next 30 days.
  • Skin damage or significant arthritis, preventing wearing of device.
  • Uncontrolled seizures or other neurological disorders leading to excessive abnormal movements or tremors in the upper body.
  • Pregnant women or those who are currently nursing.
  • Visual/cognitive impairment that as judged by the investigator does not allow the subject to independently follow rules and procedures of the protocol.

Trial locations and contacts

4 sites in 1 country.

United States4 sites
  • North Florida/South Georgia Veterans Health System, Gainesville, FL

    Gainesville, Florida, 32608-1135

  • VA Palo Alto Health Care System, Palo Alto, CA

    Palo Alto, California, 94304-1207

  • Hunter Holmes McGuire VA Medical Center, Richmond, VA

    Richmond, Virginia, 23249-0001

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah, 84148-0001

Other trials in United States

About this study

Official title: Continuous Wearable Monitoring Analytics to Improve Outcomes in Heart Failure - LINK-HF2 Multicenter Implementation Study

Heart failure (HF) is a type of heart disease that leads to need of admissions to the hospital during worsening of symptoms. These admissions are expensive and very inconvenient for patients. The investigators have previously shown that monitoring of patients with a using a small wearable sensor combined with a mathematical model can detect worsening of HF before the patient needs medical care.

In this study the investigators will test whether the remote monitoring and prediction of HF worsening can be used to find out when patients are at risk, change their treatment and avoid a hospitalization.

The study will enroll 240 Veterans with HF and randomly assign half of them to monitoring and communication of the information on HF worsening to their medical teams. The investigators hope to find our how to best use this approach in routine care of HF. The investigators also plan to determine if this approach will indeed led to less admissions to the hospital among these patients, shorter hospital stays and better quality of life.

Read the detailed description

Heart failure (HF) represents a major health burden, with 80% of the HF health care costs attributable to hospitalizations. In a pilot multicenter study funded by the VA Center for Innovation, the investigators demonstrated that multivariate physiological telemetry using a small wearable sensor has a high compliance rate and provides accurate early detection of impending readmission for HF. In this study the investigators will implement non-invasive remote monitoring within the VA system and perform a feasibility evaluation of the intervention and its programmatic effectiveness after implementation. Our hypothesis is that the implementation of this program will be feasible and acceptable to clinicians working in VA HF clinics. The investigators also hypothesize that algorithmic response to an alert generated by the predictive algorithm using a continuous stream of remote monitoring data will be feasible and provide the basis for further testing of this approach to decrease the risk of hospitalization for HF and improve other key clinical outcomes. The specific aims of our study are:

Aim 1. Implement remote monitoring into the clinical workflow of HF care. Aim 1a. Design implementation strategies for non-invasive remote monitoring and algorithmic response to clinical alerts generated by the predictive analytics platform. In HF programs at five VA medical centers, eligible patients will be enrolled at the time of hospital discharge for HF exacerbation and receive a wearable monitor and a smart phone with cellular service. Data continuously uploaded to a secure server will be analyzed by the predictive analytics algorithm and a clinical alert will be generated when physiological derangements correlated with impending HF exacerbation are identified. A clinical response algorithm will provide instructions for management response to the alert, to include medication changes and/or urgent/non-urgent outpatient assessment. The intervention will include electronic health record integration. The investigators will design implementation processes for this program using the integrated Promoting Action on Research Implementation in Health Services (i-PARiHS) framework, adapted for the VA QUERI. The investigators will design 3 phases of implementation: 1) implementation intervention planning through workflow analysis, technology assessments, and recipient/stakeholder interviews; 2) formative evaluation of pilot implementation at two vanguard sites to test initial acceptability, reliability, and equipment performance; and 3) implementation fidelity monitoring by assessing consistency, safety and satisfaction.

Aim 1b. Evaluate implementation outcomes, including clinician and patient perceptions and adoption of the use of ambulatory remote monitoring data. The investigators will use both quantitative and qualitative research methods to examine the eight core dimensions of implementation outcomes. Focus groups and semi-structured interviews will be done to assess clinician and patient perceptions of acceptability and feasibility. Adoption behaviors will be tracked including alert response rates and appropriateness of decisions. Fidelity of implementation will be monitored by assessing compliance with all aspects of the study protocol. Penetration and sustainability will be evaluated by assessing variation in implementation outcomes across the five study sites as well as participant perceptions from the qualitative work at the end of the study.

Aim 2. Conduct a feasibility study of non-invasive remote monitoring in chronic HF.

Aim 2a. Define key characteristics that will inform design of a pivotal trial of non-invasive remote monitoring aimed at reducing rehospitalization and improving quality of life in HF. The investigators will enroll 240 patients hospitalized for HF exacerbation. At enrollment, subjects will undergo 1:1 randomization to intervention or control arm. While all study subjects will use the monitoring device for 90 days after discharge, in the intervention arm, clinicians will be notified of clinical alerts and will follow the response algorithm to modify HF treatment and/or recommend urgent clinic visit/emergency room visit. In the control arm, information from the sensor will be collected, but clinical alerts will not be generated or communicated to providers. The main study outcomes will include the proportion of randomized patients who meet the algorithm's criteria for at least one alert, the proportion of time the remote monitor is in use and functioning properly, HF hospitalization rate, length of hospital stay, and health-related quality of life. Implementation factors identified in Aim 1 will help clarify the results of this aim.

Aim 2b. Identify costs associated with implementation and clinical use of non-invasive remote monitoring in HF. Correct classification of costs associated with implementation of non-invasive remote monitoring will set the stage for cost-effectiveness analyses in a future pivotal trial.

Recent advances in technology and in machine learning provide an opportunity for processing of new sources of real-time patient-level data to generate clinically actionable information. An important knowledge gap is how to best implement this technology-based approach into clinical practice. Our study addresses this critical question of clinical implementation, and will generate feasibility data for a design of a pivotal clinical trial of non-invasive remote monitoring with predictive analytics during the high-risk period after hospital discharge. This work has potential to result in changes to care of Veterans with HF and other chronic health conditions.

Conditions
Heart Failure
Being tested
Remote monitoring and predictive analytics, Sham comparator
Keywords
heart failure, remote monitoring, predictive analytics, artificial intelligence
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Remote monitoring and predictive analyticsOther

    Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.

  • Sham comparatorOther

    Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.

Study groups in NCT04502563
Study groupRoleWhat they receive
Active armExperimentalSubjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
Receives: Other: Remote monitoring and predictive analytics
ControlSham comparatorSubjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
Receives: Other: Sham comparator

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Heart Failure Hospitalization Rate

    90-day hospitalization rate in subjects in active arm vs control arm

    Measured: 90 days

Secondary outcomes (1)
  1. Kansas City Cardiomyopathy Questionaire Score

    Scale range 0-100. Higher result is better.

    Measured: 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Aug 2020
  2. Study start19 Apr 2021
  3. Primary completion31 Aug 2024
  4. Study completion30 Oct 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective randomized study
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
176 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04502563
Sponsor's protocol ID
IIR 19-238
Acronym
LINK-HF2
Status last verified
Apr 2026
First submitted
4 Aug 2020
Last updated
28 Apr 2026
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Nelson RE, Hyun D, Jezek A, Samore MH. Mortality, Length of Stay, and Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Elderly Hospitalized Patients in the United States. Clin Infect Dis. 2022 Mar 23;74(6):1070-1080. doi: 10.1093/cid/ciab696.

    PubMed 34617118
  • Sideris K, Weir CR, Schmalfuss C, Hanson H, Pipke M, Tseng PH, Lewis N, Sallam K, Bozkurt B, Hanff T, Schofield R, Larimer K, Kyriakopoulos CP, Taleb I, Brinker L, Curry T, Knecht C, Butler JM, Stehlik J. Artificial intelligence predictive analytics in heart failure: results of the pilot phase of a pragmatic randomized clinical trial. J Am Med Inform Assoc. 2024 Apr 3;31(4):919-928. doi: 10.1093/jamia/ocae017.

    PubMed 38341800
  • Aaronson KD, Stewart GC, Stevenson LW, Richards B, Khalatbari S, Cascino TC, Ambardekar AV, Stehlik J, Lala A, Kittleson MM, Palardy M, Mountis MM, Pagani FD, Jeffries N, Taddei-Peters WC, Mann DL; REVIVAL Investigators. Optimizing Triage of Ambulatory Patients With Advanced Heart Failure: 2-Year Outcomes From REVIVAL. JACC Heart Fail. 2024 Oct;12(10):1734-1746. doi: 10.1016/j.jchf.2024.05.008. Epub 2024 Jul 3.

    PubMed 38970587
  • Alba AC, Stehlik J. Dynamic Risk Prediction: A Step Closer to Personalizing Post-LVAD Care. JACC Heart Fail. 2024 Nov;12(11):1913-1914. doi: 10.1016/j.jchf.2024.08.015. Epub 2024 Oct 2. No abstract available.

    PubMed 39365236
  • Atik FA, Pego-Fernandes PM, Mejia JA, Goldraich LA, Marcondes-Braga FG, Azeka E, Figueira FA, Garcia VD, Haddad L, Cherikh W, Stehlik J, Cogswell R. ABTO Brazilian Transplant Registry and ISHLT Heart Transplant Registry: An Important/Valuable Partnership. Arq Bras Cardiol. 2025 Feb 10;122(1):e20240370. doi: 10.36660/abc.20240370. eCollection 2025. No abstract available. English, Portuguese.

    PubMed 39936696
  • Sideris K, Schmalfuss C, Lewis N, Sallam K, Bozkurt B, Hanff TC, Young MT, Schofield R, Kyriakopoulos CP, Hanson H, Brinker L, Wohlfahrt P, Mehra MR, Curry T, Knecht C, Tuckett S, Nelson RE, Zickmund SL, Butler JM, Edelberg JM, Kurio GH, Wegerich S, Serghiou S, Pipke M, Stehlik J. Artificial Intelligence-Enabled Detection and Management of Physiological Instability in Heart Failure: Results of the Randomized LINK-HF2 Trial. JACC Heart Fail. 2026 Oct 9:103422. doi: 10.1016/j.jchf.2026.103422. Online ahead of print.

    PubMed 42853165

Questions about this trial

What is this clinical trial studying?

A study testing Remote monitoring and predictive analytics in people with Heart Failure, run by VA Office of Research and Development at 4 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Heart Failure Hospitalization Rate (time frame: 90 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04502563, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in